Literature DB >> 1306810

Priming as a model of behavioural sensitization.

G Di Chiara1, M Morelli, P Barone, F Pontieri.   

Abstract

Repeated exposure to drugs acting as direct or indirect stimulants of central dopamine transmission results in sensitization to their behavioural stimulant properties (behavioural sensitization). Priming provides a simple model of behavioural sensitization particularly suitable for studies of its neural and molecular mechanisms. The results obtained to date indicate that priming results in an increased responsiveness of postsynaptic dopamine receptor mechanisms in the caudate nucleus, possibly due to an increased affinity of the D-1 receptor for its agonist.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1306810

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  5 in total

1.  Altered dopamine D2 receptor function and binding in obese OLETF rat.

Authors:  Andras Hajnal; Wojciech M Margas; Mihai Covasa
Journal:  Brain Res Bull       Date:  2007-08-08       Impact factor: 4.077

2.  Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats.

Authors:  M L Gregório; E C Wietzikoski; M M Ferro; J L M Silveira; M A B F Vital; C Da Cunha
Journal:  Neurotox Res       Date:  2009-03-18       Impact factor: 3.911

Review 3.  Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

Authors:  Agnès Nadjar; Charles R Gerfen; Erwan Bezard
Journal:  Prog Neurobiol       Date:  2008-09-30       Impact factor: 11.685

Review 4.  The 6-hydroxydopamine model of Parkinson's disease.

Authors:  Nicola Simola; Micaela Morelli; Anna R Carta
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

5.  Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.

Authors:  Laurence Mignon; William A Wolf
Journal:  Psychopharmacology (Berl)       Date:  2007-01-31       Impact factor: 4.415

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.